Controlled ovarian hyperstimulation protocols for in vitro fertilization: two decades of experience after the birth of Elizabeth Carr

被引:107
作者
Arslan, M
Bocca, S
Mirkin, S
Barroso, G
Stadtmauer, L
Oehninger, S
机构
[1] Eastern Virginia Med Sch, Jones Inst Reprod Med, Dept Obstet & Gynecol, Norfolk, VA 23507 USA
[2] Mersin Univ, Dept Obstet & Gynecol, Mersin, Turkey
[3] Inst Nacl Perinatol, Mexico City, DF, Mexico
关键词
GnRH analogues; gonadotropins; IVF; ovarian reserve; ovarian stimulation;
D O I
10.1016/j.fertnstert.2005.02.053
中图分类号
R71 [妇产科学];
学科分类号
100211 [妇产科学];
摘要
Objective: To critically discuss the current protocols for the management of controlled ovarian hyperstimulation in assisted reproduction technology. Design: Review of the literature and presentation of our experience. Main Outcome Measure(s): ovarian response (peak serum estrogen levels, number of oocytes retrieved, quality of oocytes and embryos) and pregnancy outcome (clinical, delivery, and multiple pregnancy rates). Result(s): Controversies still exist regarding selection of gonadotropin preparation, choice of adjuvant therapy with GnRH analogues, and use of oral contraceptive pills. Patients identified as intermediate responders have,an excellent outcome with adjuvant therapy with either a GnRH agonist (long protocol) or a GnRH antagonist, but tailoring of gonadotropin dose must be performed to achieve optimized results. High responders perform favorably with gentler gonadotropin stimulation that minimizes the occurrence of ovarian hyperstimulation syndrome. On the other hand, results in low responders remain suboptimal both in terms of ovarian response and oocyte/embryo quality in spite of a variety of stimulation regimens used. Conclusion(s): Ovarian stimulation is a critical step in in vitro fertilization therapy. A variety of controlled, ovarian hyperstimulation regimens are available and efficacious, but individualization of management is essential and depends on assessment of the ovarian reserve. Identification of the etiologies of poor olvarian response, constitutes a formidable challenge facing reproductive endocrinologists.
引用
收藏
页码:555 / 569
页数:15
相关论文
共 132 条
[1]
ABBASI R, 1987, FERTIL STERIL, V47, P1019
[2]
Increasing the dose of human menopausal gonadotrophins on day of GnRH antagonist administration: randomized controlled trial [J].
Aboulghar, MA ;
Mansour, RT ;
Serour, GI ;
Al-Inany, HG ;
Amin, YM ;
Aboulghar, MM .
REPRODUCTIVE BIOMEDICINE ONLINE, 2004, 8 (05) :524-527
[3]
Adashi Eli Y, 2003, Reprod Biomed Online, V7, P515
[4]
Follicle-stimulating hormone or human menopausal gonadotropin for ovarian stimulation in in vitro fertilization cycles: a meta-analysis [J].
Agrawal, R ;
Holmes, J ;
Jacobs, HS .
FERTILITY AND STERILITY, 2000, 73 (02) :338-343
[5]
Addition of GnRH antagonist in cycles of poor responders undergoing IVF [J].
Akman, MA ;
Erden, HF ;
Tosun, SB ;
Bayazit, N ;
Aksoy, E ;
Bahceci, M .
HUMAN REPRODUCTION, 2000, 15 (10) :2145-2147
[6]
GnRH antagonist in assisted reproduction: a Cochrane review [J].
Al-Inany, H ;
Aboulghar, M .
HUMAN REPRODUCTION, 2002, 17 (04) :874-885
[7]
Ovarian stimulation with HMG:: results of a prospective randomized phase III European study comparing the luteinizing hormone-releasing hormone (LHRH)-antagonist cetrorelix and the LHRH-agonist buserelin [J].
Albano, C ;
Felberbaum, RE ;
Smitz, J ;
Riethmüller-Winzen, H ;
Engel, J ;
Diedrich, K ;
Devroey, P .
HUMAN REPRODUCTION, 2000, 15 (03) :526-531
[8]
Comparison of different doses of gonadotropin-releasing hormone antagonist Cetrorelix during controlled ovarian hyperstimulation [J].
Albano, C ;
Smitz, J ;
Camus, M ;
RiethmullerWinzen, H ;
VanSteirteghem, A ;
Devroey, P .
FERTILITY AND STERILITY, 1997, 67 (05) :917-922
[9]
[Anonymous], 1998, J Clin Endocrinol Metab, V83, P1507
[10]
[Anonymous], 2000, Hum Reprod, V15, P1446